BioSpace News Archive

NLS Pharmaceutics Ltd. is pleased to announce its participation in the following upcoming conferences: 2023 BIO CEO Investor Conference.

Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of the CE mark for its VYRA CoV2Flu Antigen Test.

Athersys, Inc. (NASDAQ: ATHX) announced today their participation in two January conferences, Advanced Therapies Week presented by Phacilitate from January 17-20, 2023 in Miami, FL and the 2nd Allogeneic Cell Therapies Summit Europe from January 30-February 1, 2023 in London, UK.

LightForce is proud to announce that Dr. Alfred Griffin, CEO of LightForce, will have the great opportunity of speaking at the JP Morgan Healthcare Conference on January 11th, 2023, in San Francisco, CA.

ZyVersa Therapeutics, Inc. announced that Stephen C. Glover, ZyVersa’s Co-founder, Chairman, Chief Executive Officer, and President, will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023 at 2:00 PM ET.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) announced today the company has initiated the KAIZEN clinical study of its Diamondback 360© Peripheral Orbital Atherectomy System (OAS) for the treatment of calcified plaque in patients with peripheral artery disease (PAD).

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the closing of its previously announced public offering of an aggregate of 2,586,207 shares of its common stock (or pre-funded warrants in lieu thereof).

Lifecore Biomedical, Inc., announced that it received a notice on January 11, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250 because the Company failed to timely file its Quarterly Report on Form 10-Q for the quarter ended November 27, 2022 with the Securities and Exchange Commission.

PTC Therapeutics, Inc. announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an aggregate of 39,585 shares of its common stock and 13,045 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 33 new employees.

Savaria Corporation a global leader in the accessibility industry, announces that Ms. Anne Le Breton will be joining its Board of Directors effective as of the date hereof.